Value contribution of leniolisib in the Treatment of Activated PI3Kδ syndrome (APDS) in Spain using Multi-Criteria Decision Analysis (MCDA)
Based on MCDA methodology and stakeholder experience in APDS management, leniolisib is seen as a value-added treatment option compared to SoC in Spain.
Authors
- K Herrmann (ORCID: https://orcid.org/0000-0002-9701-2854)
- Olaf Neth (ORCID: https://orcid.org/0000-0001-5018-0466)
- Alicia Gil (ORCID: https://orcid.org/0000-0003-3006-7858)
- Carlos Rodríguez‐Gallego (ORCID: https://orcid.org/0000-0002-4344-8644)
- José Luís Trillo (ORCID: https://orcid.org/0000-0002-5851-9038)
- Carmen Alerany
- María Reyes Abad Sazatornil (ORCID: https://orcid.org/0000-0001-5527-9668)
- Luis Ignacio González‐Granado (ORCID: https://orcid.org/0000-0001-6917-8980)
- Concepción Payares‐Herrera (ORCID: https://orcid.org/0009-0001-7041-1564)
- Raquel Figueiredo
Institutions
- Universidad de Las Palmas de Gran Canaria (ES)
- Research Institute Hospital 12 de Octubre (ES)
- Universidad Fernando Pessoa Canarias (ES)
- Hospital Universitario de Gran Canaria Doctor Negrín (ES)
- Hospital Universitario Puerta de Hierro Majadahonda (ES)
- Oblikue Consulting (Spain) (ES)
- Hospital Universitario Miguel Servet (ES)
- Pharming Group (Netherlands) (NL)
- Hospital Universitario Virgen del Rocío (ES)
Publication Details
- Journal
- Global & Regional Health Technology Assessment
- Published
- 2025-01-27
- DOI
- https://doi.org/10.33393/grhta.2025.3199
- Citations
- 1
- Primary Topic
- Chronic Lymphocytic Leukemia Research
- Type
- article
- Field-Weighted Citation Impact
- 1.63